Imaging Techniques, Patient Preparation And Reporting Of Pet

Positron emission tomography (PET) is a noninvasive quantitative biochemical and functional imaging method. The most frequently used radiopharmaceutical for this method is F-18 fluorodeoxyglucose (FDG). FDG PET/BT constitutes 95% of routine practice applications. The maximum benefit with PET/CT of visual and quantitative evaluation is provided with standardization of patient preparation, imaging technique, and interpretation. The ultimate goal of creating a consensus in request information, patient preparation, radiopharmaceutical dosage and administration, imaging, evaluation, and reporting was reproducibility and repeatability of exam. The European Association of Nuclear Medicine (EANM) defined as EANM Research Ltd. (EARL) includes the absolute criteria for imaging optimization and stability. The Society of Nuclear Medicine (SNM) and EANM share the current consensuses regularly. FDG PET/CT is the most widely used for the evaluation of treatment response. The European Organization of Research and Treatment of Cancer (EORTC) and the PET Response Criteria in Solid Tumors (PERCIST) were published as general evaluation criteria, and the Deauville criteria were defined in the interim therapy evaluation of Hodgkin lymphomas. Differential diagnosis and additional tests that are suggested to contribute to the diagnosis should be indicated. All morphological information on the location of the pathological uptake must be defined in the report. PET/CT reports should be written with a high probability of diagnosis and, if possible, with tumor staging.